ChartMill · Sep 18, 2026
Top stock movements in today's session.
Keep an eye on the top gainers and losers in Friday's session, as they reflect the most notable price movements.
BC
NASDAQ · BCTXZ
BriaCell Therapeutics Corp. Warrant
Healthcare · Biotechnology
$0.17
Up+$0.02 (+13.53%)
Updated Sep 19, 2026, 4:42 PM
SID Score
5.5/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 753.16K
- P/E ratio
- -1.99
- Dividend yield
- 0.00%
- 52-week range
- $0.06 – $0.25
- Volume
- 10.74K
- Avg. volume
- 21.5K
Price performance
BCTXZ price history
1M range · 20 trading sessions · Daily adjusted prices
BCTXZ closed at $0.17 after 20 trading sessions, up 62.19% for the selected period.
- Last close
- $0.17
- Period change
- +62.19%
- Period low
- $0.11
- Period high
- $0.21
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 18, 2026 | $0.1697 | $0.2647 | $0.1504 | $0.1703 | 10.74K |
| Sep 17, 2026 | $0.1376 | $0.15 | $0.1211 | $0.15 | 30.54K |
| Sep 16, 2026 | $0.1325 | $0.1485 | $0.1325 | $0.1485 | 3.85K |
| Sep 15, 2026 | $0.14 | $0.15 | $0.121 | $0.144 | 47.81K |
| Sep 14, 2026 | $0.13 | $0.1301 | $0.1114 | $0.1301 | 2.25K |
| Sep 11, 2026 | $0.12 | $0.1456 | $0.102 | $0.1441 | 188.87K |
| Sep 10, 2026 | $0.1379 | $0.14 | $0.1124 | $0.125 | 31.14K |
| Sep 9, 2026 | $0.1201 | $0.14 | $0.1019 | $0.1399 | 51.49K |
| Sep 8, 2026 | $0.169 | $0.169 | $0.14 | $0.1401 | 55.27K |
| Sep 4, 2026 | $0.19 | $0.19 | $0.1801 | $0.185 | 6.35K |
| Sep 3, 2026 | $0.191 | $0.25 | $0.1777 | $0.1895 | 21.14K |
| Sep 2, 2026 | $0.1825 | $0.25 | $0.175 | $0.2111 | 27.41K |
| Sep 1, 2026 | $0.16 | $0.20 | $0.1501 | $0.187 | 17.05K |
| Aug 31, 2026 | $0.1644 | $0.1699 | $0.1311 | $0.15 | 20.82K |
| Aug 28, 2026 | $0.15 | $0.156 | $0.1259 | $0.135 | 13.36K |
| Aug 27, 2026 | $0.1202 | $0.1673 | $0.1202 | $0.1202 | 14.38K |
| Aug 26, 2026 | $0.12 | $0.15 | $0.12 | $0.1254 | 39.92K |
| Aug 25, 2026 | $0.121 | $0.13 | $0.11 | $0.115 | 20.15K |
| Aug 24, 2026 | $0.12 | $0.14 | $0.1059 | $0.11 | 34.64K |
| Aug 21, 2026 | $0.112 | $0.1731 | $0.105 | $0.105 | 37.64K |
Latest BCTXZ news
The latest Smart Investors Daily articles mentioning BCTXZ.
Stock researchCompany · Overview
BCTXZ research
Overview
Company profile and research snapshot.
Company profile
BriaCell Therapeutics Corp is a clinical-stage biotechnology company focused on developing immunotherapies for cancer treatment, particularly breast cancer. The company's targeted immunotherapy program, Bria-IMT, is a targeted cell-based immunotherapy in end-stage clinical trials aiming to improve outcomes for patients with breast cancer. BriaCell also develops Bria-OTS, personalized off-the-shelf immunotherapies for breast and prostate cancer. BriaCell is involved in clinical collaborations to explore combination therapies for enhanced cancer treatment options.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- —
- Implied upside
- —
- Analysts
- —
News briefing
Generated Sep 19, 2026, 3:08 PM
Why Is BCTXZ Up Today?
BriaCell Therapeutics warrant shares gained 13.53% in today's session, reflecting modest upward momentum in the biotech space. However, the limited headline coverage suggests this move may be driven more by broader market positioning or technical factors rather than company-specific catalysts.
Bottom line: Today's 13.53% warrant gain appears to be driven primarily by technical positioning and broader biotech sector momentum rather than company-specific developments. While the move is noteworthy, investors should demand concrete clinical or regulatory catalysts before considering this a meaningful investment signal, and remain mindful of warrant-specific risks including time decay and leverage.
ChartMill · Sep 18, 2026
Friday's session: gap up and gap down stocks
Let's have a look at the gap up and gap down stocks in today's session.
Yahoo · Sep 14, 2026
Data Safety Monitoring Board (DSMB) Recommends Continuing BriaCell’s Phase 3 Metastatic Breast Cancer Study
Independent DSMB reports no safety concerns to date and recommends continuing BriaCell's pivotal Phase 3 study of Bria-IMT™ plus an immune checkpoint inhibitorSeventh consecutive positive DSMB recommendation reinforces the favorable safety and tolerability of BriaCell's novel immunotherapy approachPhase 3 study is being conducted under FDA Fast Track designation, underscoring the substantial unmet need in metastatic breast cancer PHILADELPHIA and VANCOUVER, British Columbia, Sept. 14, 2026 (GLOB
ChartMill · Sep 9, 2026
Gapping stocks in Wednesday's session
The market is buzzing with gapping stocks on Wednesday. Let's uncover which stocks are experiencing notable gaps during today's session.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
